{"id":56539,"date":"2026-02-06T22:08:38","date_gmt":"2026-02-06T14:08:38","guid":{"rendered":"https:\/\/flcube.com\/?p=56539"},"modified":"2026-02-06T22:08:39","modified_gmt":"2026-02-06T14:08:39","slug":"ascentage-pharma-secures-nmpa-approval-for-apg-3288-btk-degrader-trial-in-hematologic-malignancies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56539","title":{"rendered":"Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies"},"content":{"rendered":"\n<p><strong>Ascentage Pharma Group International<\/strong> (<strong><a href=\"https:\/\/www.google.com\/finance\/quote\/AAPG:NASDAQ\">NASDAQ: AAPG<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/6855:HKG\">HKG: 6855<\/a><\/strong>) announced that China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong> has granted <strong>clinical trial approval<\/strong> for <strong>APG\u20113288<\/strong>, a <strong>BTK\u2011targeted protein degrader<\/strong>, in patients with <strong>relapsed\/refractory hematologic malignancies<\/strong>. The asset previously received <strong>US IND clearance<\/strong>, marking Ascentage\u2019s progress in dual\u2011jurisdiction development.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China) \/ CDE (Center for Drug Evaluation)<\/td><\/tr><tr><td><strong>Asset<\/strong><\/td><td>APG\u20113288 (BTK PROTAC protein degrader)<\/td><\/tr><tr><td><strong>Approval<\/strong><\/td><td>Phase I clinical trial authorization<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Relapsed\/refractory hematologic malignancies<\/td><\/tr><tr><td><strong>Global Status<\/strong><\/td><td>US IND previously cleared; China approval now secured<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-platform-amp-mechanism-of-action\">Technology Platform &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Platform:<\/strong> <strong>Proteolysis Targeting Chimera (PROTAC)<\/strong> \u2013 Ascentage proprietary protein degradation technology<\/li>\n\n\n\n<li><strong>Target:<\/strong> <strong>Bruton\u2019s tyrosine kinase (BTK)<\/strong> \u2013 Critical signaling node in B\u2011cell receptor pathway, validated in lymphoid malignancies<\/li>\n\n\n\n<li><strong>Degradation Mechanism:<\/strong><\/li>\n<\/ul>\n\n\n\n<ol class=\"wp-block-list\">\n<li>Forms <strong>ternary complex<\/strong> (BTK\u2011PROTAC\u2011Cereblon E3 ubiquitin ligase)<\/li>\n\n\n\n<li>Recruits E3 ligase to tag BTK with ubiquitin<\/li>\n\n\n\n<li><strong>Proteasome\u2011mediated degradation<\/strong> eliminates BTK protein entirely<\/li>\n<\/ol>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Advantage:<\/strong> Functional protein elimination (vs. reversible inhibition) may overcome resistance mutations seen with traditional BTK inhibitors<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-study-design\">Clinical Study Design<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Specification<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Type<\/strong><\/td><td>Multicenter, open\u2011label Phase I<\/td><\/tr><tr><td><strong>Primary Endpoints<\/strong><\/td><td>Safety, tolerability, pharmacokinetic (PK) profile<\/td><\/tr><tr><td><strong>Secondary Endpoints<\/strong><\/td><td>Preliminary efficacy signals (ORR, DOR)<\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Relapsed\/refractory hematologic malignancies (B\u2011cell lymphomas, potential CLL expansion)<\/td><\/tr><tr><td><strong>Sites<\/strong><\/td><td>Multiple centers across China<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-positioning-amp-market-context\">Strategic Positioning &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>PROTAC Competitive Landscape:<\/strong> APG\u20113288 enters a <strong>rapidly evolving BTK degrader race<\/strong> against Nurix (NX\u20112127), C4 Therapeutics (CFT8916), and others, with first\u2011generation BTK inhibitors (ibrutinib, zanubrutinib) establishing target validation but facing resistance limitations.<\/li>\n\n\n\n<li><strong>Degrader Differentiation:<\/strong> Unlike reversible or covalent BTK inhibitors, <strong>PROTAC\u2011mediated degradation<\/strong> eliminates both wild\u2011type and mutant BTK proteins, potentially addressing <strong>C481S mutation\u2011driven resistance<\/strong> that limits incumbent therapies.<\/li>\n\n\n\n<li><strong>Dual\u2011Listing Advantage:<\/strong> Ascentage\u2019s <strong>NASDAQ\/HKEX dual listing<\/strong> provides access to US and Asian capital markets, supporting global trial expansion and potential US\u2011China parallel development strategy.<\/li>\n\n\n\n<li><strong>Hematology Pipeline Synergy:<\/strong> APG\u20113288 complements Ascentage\u2019s established <strong>BCL\u20112 inhibitor (lisaftoclax)<\/strong> and <strong>MDM2\u2011p53 inhibitor (alrizomadlin)<\/strong> portfolio, creating combination potential in relapsed\/refractory B\u2011cell malignancies.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-development-roadmap\">Development Roadmap<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Phase<\/th><th>Milestone<\/th><th>Anticipated Timing<\/th><\/tr><\/thead><tbody><tr><td><strong>Current<\/strong><\/td><td>China Phase I initiation (NMPA approved)<\/td><td>Q1 2026<\/td><\/tr><tr><td><strong>Parallel<\/strong><\/td><td>US Phase I ongoing (previously cleared)<\/td><td>Active enrollment<\/td><\/tr><tr><td><strong>Future<\/strong><\/td><td>Dose expansion and combination cohorts<\/td><td>2026\u20112027<\/td><\/tr><tr><td><strong>Strategic<\/strong><\/td><td>Potential Big Pharma partnership discussions<\/td><td>Data\u2011dependent<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding APG\u20113288 clinical development timelines, efficacy outcomes in hematologic malignancies, and Ascentage Pharma\u2019s global regulatory strategy. Actual results may differ due to trial execution risks, competitive dynamics in the BTK degrader space, and regulatory review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) announced that China\u2019s National Medical Products Administration&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[200,62,985,3273,70],"class_list":["post-56539","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-ascentage-pharma","tag-clinical-trial-approval-initiation","tag-hkg-6855","tag-nasdaq-aapg","tag-tpd"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical trial approval for APG\u20113288, a BTK\u2011targeted protein degrader, in patients with relapsed\/refractory hematologic malignancies. The asset previously received US IND clearance, marking Ascentage\u2019s progress in dual\u2011jurisdiction development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56539\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies\" \/>\n<meta property=\"og:description\" content=\"Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical trial approval for APG\u20113288, a BTK\u2011targeted protein degrader, in patients with relapsed\/refractory hematologic malignancies. The asset previously received US IND clearance, marking Ascentage\u2019s progress in dual\u2011jurisdiction development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56539\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-06T14:08:38+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-06T14:08:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56539#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56539\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies\",\"datePublished\":\"2026-02-06T14:08:38+00:00\",\"dateModified\":\"2026-02-06T14:08:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56539\"},\"wordCount\":440,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Ascentage Pharma\",\"Clinical trial approval \\\/ initiation\",\"HKG: 6855\",\"NASDAQ: AAPG\",\"TPD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56539#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56539\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56539\",\"name\":\"Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-02-06T14:08:38+00:00\",\"dateModified\":\"2026-02-06T14:08:39+00:00\",\"description\":\"Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical trial approval for APG\u20113288, a BTK\u2011targeted protein degrader, in patients with relapsed\\\/refractory hematologic malignancies. The asset previously received US IND clearance, marking Ascentage\u2019s progress in dual\u2011jurisdiction development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56539#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56539\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56539#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies - Insight, China&#039;s Pharmaceutical Industry","description":"Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical trial approval for APG\u20113288, a BTK\u2011targeted protein degrader, in patients with relapsed\/refractory hematologic malignancies. The asset previously received US IND clearance, marking Ascentage\u2019s progress in dual\u2011jurisdiction development.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56539","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies","og_description":"Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical trial approval for APG\u20113288, a BTK\u2011targeted protein degrader, in patients with relapsed\/refractory hematologic malignancies. The asset previously received US IND clearance, marking Ascentage\u2019s progress in dual\u2011jurisdiction development.","og_url":"https:\/\/flcube.com\/?p=56539","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-06T14:08:38+00:00","article_modified_time":"2026-02-06T14:08:39+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56539#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56539"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies","datePublished":"2026-02-06T14:08:38+00:00","dateModified":"2026-02-06T14:08:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56539"},"wordCount":440,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Ascentage Pharma","Clinical trial approval \/ initiation","HKG: 6855","NASDAQ: AAPG","TPD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56539#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56539","url":"https:\/\/flcube.com\/?p=56539","name":"Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-02-06T14:08:38+00:00","dateModified":"2026-02-06T14:08:39+00:00","description":"Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) announced that China\u2019s National Medical Products Administration (NMPA) has granted clinical trial approval for APG\u20113288, a BTK\u2011targeted protein degrader, in patients with relapsed\/refractory hematologic malignancies. The asset previously received US IND clearance, marking Ascentage\u2019s progress in dual\u2011jurisdiction development.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56539#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56539"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56539#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma Secures NMPA Approval for APG\u20113288 BTK Degrader Trial in Hematologic Malignancies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56539","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56539"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56539\/revisions"}],"predecessor-version":[{"id":56540,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56539\/revisions\/56540"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56539"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56539"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56539"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}